Efficacy and Safety of CUSA-081 in the Restoration of Central Venous Access Device (CVAD) Functionality

Study Identifier:
CUSA-081-HEM-01
ClinicalTrials.gov Identifier:
NCT03594175
EudraCT Identifier:
2019-002124-32
EU CT ID:
N/A
Study Contact Information:
N/A
Terminated/Withdrawn

Trial Documents

Protocol
Available Languages: English
Download document(s)
Statistical Analysis Plan
Available Languages: English
Download document(s)
Plain Language Summary
Available Languages: English, Spanish (Argentina), French (Belgium), Portuguese (Brazil), Czech, Flemish, Polish, Romanian, Spanish, Spanish (United States)
Download document(s)

Study Details

Medical Condition
  • Thrombosis
Study Drug
  • Drug: CUSA-081
  • Drug: Placebo
  • Drug: Alteplase
Date
Feb 2020 - Jun 2023
Phase 1
Phase 2
Phase 3
Phase 4
N/A
Patient Requirements
Sex: Female & Male
Age: 18+ years
Requirements Information
Inclusion and Exclusion Criteria
Inclusion Criteria
  • Inability to have 3 mL of blood withdrawn from the selected study catheter;
  • A single or multi-lumen CVAD, implanted ports or peripherally inserted central catheters (PICCs) in place for \> 24 hours and documented as previously being patent and functional;
  • Ability to designate one dysfunctional lumen of a multi-lumen catheter to be used throughout the study for both study drug instillation and assessment of CVAD function;
  • Male and non-pregnant female subjects from all racial and ethnic groups 18 years of age and older;
  • Able to have fluids infused at the volume necessary to instil study drug into the CVAD (i.e., up to 2 mL);
  • Informed consent form (ICF) signed and dated indicating that the subject has been informed of and agreed with all pertinent aspects of the study and is willing to comply with all study requirements and procedures.
Exclusion Criteria
  • CVAD (any type) used for hemodialysis;
  • CVAD known to be dysfunctional for more than 48 hours;
  • Reasonable evidence of mechanical or non-thrombotic occlusion in the selected study catheter (e.g., catheter malposition or migration, sutures, kinks, or precipitates causing obstruction), radiographic assessment is not required;
  • Known or suspected catheter related bloodstream infection (CRBSI);
  • Use of any fibrinolytic agent or anticoagulant (e.g., alteplase, tenecteplase, reteplase, urokinase or heparin) within 24 hours prior to the treatment period (first instillation of study drug). Use of subcutaneous low molecular weight heparin (LMWH) for prophylaxis of thromboembolic events is allowed;
  • Known to be at high risk for bleeding events or embolic complications in the opinion of the Investigator, or has a known condition for which bleeding constitutes a significant hazard (e.g. recent stroke, recent intracranial or intraspinal surgery or serious head trauma, intracranial neoplasm, arteriovenous malformation or aneurysm, known bleeding diathesis);
  • Uncontrolled hypertension (systolic BP ≥160 or diastolic BP ≥110 mmHg) at screening;
  • Clinically unstable in the opinion of the site investigator;
  • Known to be pregnant or breastfeeding at screening;
  • Previously treated in this study (READY 1) or in study READY 2;
  • History of allergic reaction to reteplase, alteplase or vial ingredients (excipients or diluents);
  • Use of any investigational drug or experimental medical device within 28 days prior to treatment; non interventional observational studies participation is allowed.
  • Not mentally, socially, or otherwise able to complete the trial assessment or not likely to survive beyond 30 days.
Healthy Volunteers
No

Protocol Summary

To evaluate the efficacy and safety of CUSA-081 (diluted reteplase) in the restoration of central venous access device (CVAD) functionality in participants 18 years and older.

Study Locations

Location
Status
Location
Chiesi Investigational Site
Little Rock, Arkansas, United States, 72205
Status
N/A
Location
Chiesi Investigational Site
Redlands, California, United States, 92373
Status
N/A
Location
Chiesi Investigational Site
Stockton, California, United States, 95204
Status
N/A
Location
Chiesi Investigational Site
Norwich, Connecticut, United States, 06360
Status
N/A
Location
Chiesi Investigational Site
Newark, Delaware, United States, 19718
Status
N/A
Location
Chiesi Investigational Site
Jacksonville, Florida, United States, 32209
Status
N/A
Go to page